Chris Sampson’s journal round-up for 14th August 2017

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Does paying service providers by results improve recovery outcomes for drug misusers in treatment in England? Addiction [PubMedPublished 10th August 2017

‘Getting what you pay for’ is a fundamentally attractive funding model, which is why we see lots of pay for performance (P4P) initiatives cropping up in the NHS. But P4P plans can go awry. This study considers an experimental setting in which 8 areas participated in P4P pilots for drug misuse treatment, from 2012-2014. Payments were aligned with 3 national priorities: i) abstinence, ii) reduced offending and iii) improved health and well-being. The participating areas allocated differing proportions of payments to the P4P model, between 10% and 100%. Data were drawn from the National Drug Treatment Monitoring System, which includes information on drug use, assessment and interventions received. Other national sources were used to identify criminal activity and mortality rates. Drug misusers attending treatment services during the 2 years before and after the introduction of the P4P scheme were included in the study. Using a difference-in-differences analysis, the researchers compared outcomes in the 8 participating areas with those in 143 non-participating areas. Separate multilevel regression models were used for a set of outcomes, each controlling for a variety of individual-level characteristics. The authors analysed ‘treatment journeys’, of which there were around 20,000 for those in participating areas and 280,000 for those in non-participating areas; roughly half before the introduction and half after. The results don’t look good for P4P. Use of opiates, crack cocaine and injecting increased. Treatment initiation increased in non-participating areas but decreased in participating areas. Moreover, longer waiting times were observed in participating areas as well as more unplanned discharges. P4P was associated with people being less likely to successfully complete treatment within 12 months. In P4P’s favour, there was evidence that abstinence increased. I’d’ve liked to have seen some attempt at matching between the areas, given that there was an element of self-selection into the scheme. Or at least, better control for the characteristics of the areas before P4P was introduced. This paper isn’t quite the final nail in the coffin. I don’t see P4P disappearing anytime soon. There’s a lot to be learnt from the paper’s discussion, which outlines some of the likely reasons and mechanisms underlying the findings. Commissioners should take note.

The short- and long-run effects of smoking cessation on alcohol consumption. International Journal of Health Economics and Management [PubMedPublished 7th August 2017

Anecdotally, it seems as if smoking and drinking are complementary behaviours. Generally, the evidence suggests that this is true. Smoking cessation programmes may, therefore, have value in their ability to reduce alcohol consumption (and vice versa). But only if the relationship is causal. This study seeks to add to that causal evidence. Using data from 5887 individuals in the Lung Health Study, the author runs a two-stage least squares estimation, with randomisation to smoking cessation treatment as an instrumental variable for smoking status. In the short term, there is some evidence that smokers tend to drink more (especially men). But findings in the longer term, up to 5 years, are more persuasive. It’s unfortunate that the (largely incoherent) rational addiction theory makes an appearance and that the findings are presented as supportive of it. A stopped clock is right twice a day. In line with rational addiction theory, the long-term relationship is measured in terms of a ‘smoking stock’, which is an aggregate measure of smoking behaviour over the 5 year period. Smoking and drinking are found to be complementary in the long term. Crucially, the extent of their complementarity is associated with particular factors. For example, people who smoke more cigarettes or who abstain for longer exhibit larger reductions in alcohol consumption when they stop smoking. People who smoke relatively few cigarettes per day do not drink more alcohol. Those smoking 6-10 per day consume around 1 extra drink per week compared with non-smokers. Quitting for 5 years can reduce alcohol consumption by more than 50%. In the long run, the effect is more pronounced for women and for people who are married. This highlights important opportunities for targeted public policy, which could achieve a win-win in terms of reducing both cigarette and alcohol consumption.

Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy Published 5th August 2017

Antibiotics have become a key component of health care, but antimicrobial resistance threatens their usefulness and we don’t see new antibiotics in the pipeline to help overcome this. It’s a fundamentally difficult problem; we want new antibiotics but we want to use them as sparingly as possible. Antibiotic development is relatively unattractive (financially) to pharmaceutical companies. Provision of research funding and regulatory changes haven’t solved the problem to date. This paper considers why this might be the case, and explores 2 alternative approaches: a premium price model and an insurance-type model. Essentially, the authors conduct a spreadsheet analysis to compare the alternative models with a base case of no incentives. The expected net present value of the base case was negative (to the tune of about $1.5 billion), demonstrating why much-needed new antibiotics aren’t being developed. Current incentives – including public-private funding partnerships and market exclusivity – are also shown to fail to reach a positive net present value. The premium price model, whereby there is an enhanced price per unit, is not particularly attractive. The daily cost of the resulting antibiotics would likely be too high, and manufacturers’ pursuit of profit would be at odds with conservative prescribing. Furthermore, it exposes areas experiencing outbreaks to serious financial risk. The insurance model, which involved an annual fee paid by each healthcare system (to manufacturers), is more promising. Pharmaceutical companies would be insured against low prices and variable use and health systems would be insured against a lack of antibiotics and the risk of an infection outbreak. The key feature here is that manufacturers’ revenues are de-linked from sales volume. This is important when we consider the need for conservative prescribing. The authors estimate that the necessary fee (for the global market) would be around $262 million per year, or $114 million if combined with current funding and regulatory incentives. Of course, these findings are based on major assumptions about infection rates, research costs and plenty besides. A number of sensitivity analyses are conducted that highlight uncertainty about what the insurance fee might need to be in the future. I think this uncertainty is somewhat understated – there are far more sensitivity and scenario analyses that would be warranted if such a policy were being seriously considered. Nevertheless, pooling risk in an insurance model looks like a promising strategy that’s worthy of further investigation and piloting.

Credits

Paul Mitchell’s journal round-up for 26th December 2016

Every Monday (even if it’s Boxing Day here in the UK) our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Out-migration and attrition of physicians and dentists before and after EU accession (2003 and 2011): the case of Hungary. European Journal of Health Economics [PubMedPublished 2nd December 2016

Medical staff migration is an important cross-national policy issue given the international shortage of supply of doctors to meet healthcare demand. This study uses a large administrative survey collected in Hungary from 2004-2011 and focuses on the trends of medical doctors (GPs, specialists, dentists) since Hungary joined the EU in 2004 and the introduction of full freedom of movement between Hungary with Austria and Germany in 2011. The author conducted a time-to-event analysis with monthly collection of data on a person’s occupation used as a guide for outward-migration. A competing-risks model was used to also consider medical doctors exiting the profession, becoming inactive or dying. From the 18,266 medical doctors found in this sample over the nine year period, 12% migrated, 17% exited the profession and 14% became inactive. A five-fold increase in migration was seen when the restrictions on freedom of movement between Hungary and Austria/Germany were lifted, a worrying sign of brain drain from Hungary. For those who stayed but exited the profession, relative income is argued to have been a contributory factor, with incomes increasing by on average 40% in their new line of work (although this does not account for the “thank you money” received by doctors in Hungary for healthcare access). Generous maternity leave was argued to play a key role in absence from employment. A recognised limitation in this study is the inability to conduct robust analysis on the migration patterns of new medical graduates who are likely to be more prone to migration than their established colleagues (estimated to be 40% of all medical graduates in Hungary between 2007-2010 who migrated, before restrictions on freedom of movement between Austria and Germany were lifted). Nonetheless, the study still manages to shine a light on the external (competing against countries with larger economies) but also the internal (“attrition and feminisation of workforce”) challenges to national doctor staffing policy.

Does the proportion of pay linked to performance affect the job satisfaction of general practitioners? Social Science & Medicine [PubMedPublished 24th November 2016

The impact of pay for performance (P4P) on healthcare practice has been subject to much debate surrounding the pros and cons of incentives for medical staff to achieve specific goals. This study focuses on the impact that the introduction of the Quality and Outcomes Framework (QOF) for GPs in the UK in 2004 had on their subsequent job satisfaction. Job satisfaction for GPs is argued to be an important topic area due to it having an important role in retaining GPs and the quality of care they provide to their patients. Using linked data from the the GP Worklife Survey and the QOF, that rewards GPs performance based on clinical, organisation, additional services and patient experience indicators, across three time points (2004, 2005 and 2008), the authors model the relationship between P4P exposure (i.e. the proportion of income related to performance) and job satisfaction. Using a continuous difference-in-difference model with a random effects regression, the authors find that P4P exposure has no significant effect on job satisfaction after 1 and 4 years following the introduction of the QOF P4P system. The introduction of the QOF did lead to a large increase in GP life satisfaction; this is likely to be due to the large increase in average income for GPs following the introduction of QOF. The authors argue that their findings suggest GP job satisfaction is unlikely to be affected by changes in P4P exposure, so long as the final income the GP receives remains constant. Given the generous increases on GP final income from the initial QOF, it remains to be seen how generalisable these results would be to P4P systems that did not lead to such large increases in staff income.

Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value in Health [PubMed] Published 14th December 2016

National thresholds used to determine if a health intervention is cost-effective have been under scrutiny in the UK in recent years. It has been argued on the grounds of healthcare opportunity costs that the NICE £20,000-30,000 per QALY gained threshold is too high, with an estimate of £13,000 per QALY gain proposed instead. Until now, less attention has been paid to international cost-effectiveness thresholds recommended by the WHO, who have argued for a threshold between one and three times the GDP of a country. This study provides preliminary estimates of cost-effectiveness thresholds across a number of countries with varying levels of national income. Using estimates from the recent £13,000 per QALY gain threshold study in England, a ratio between the supply-side threshold with the consumption value of health was estimated and used as a basis to calculate other national thresholds. The authors use a range of income elasticity estimates for the value placed on a statistical life to take account of uncertainty around these values. The results suggest that even the lower end of the WHO recommended threshold range of 1x national GDP is likely to be an overestimate in most countries. It would appear something closer to 50% of GDP may be a better estimate, albeit with a great amount of uncertainty and variation between high and low income countries. The importance of these estimates according to the authors is that the application of the current WHO thresholds could lead to policies that reduce instead of increase population health. However, the threshold estimates from this study rely on a number of assumptions based on UK data that may not provide an accurate estimate when setting cost-effectiveness thresholds at an international level.

Credits